Annual Report

It It has been a very busy and productive year for the UKMS Guidelines group with the publication of the guidelines on “The Management of relapsed multiple myeloma: A BSH and UK Myeloma Society Guideline” in October 2025. We are fortunate to have an increasing number of therapeutic options available to manage myeloma and this guideline will be invaluable to support clinicians through the complicated decisions required to choose the best treatment for each patient. 

The guidelines on “Early diagnosis of AL Amyloidosis in Haematology, Cardiology, Neurology, Renal and general clinics: A BSH Good Practice Paper” have been submitted for publication and the guideline on “Management of Myeloma related bone disease” is in the final stages prior to submission. 

We also have writing groups working on a guideline the use of bispecific antibodies in relapsed/refractory myeloma and optimal laboratory diagnostics for multiple myeloma. Updates on the guideline for initial treatment of myeloma and guideline on management of late-effects and supportive care in myeloma are also in progress.

Thank to you all Executive members and colleagues who have supported the production of these guidelines.

Dr Tracey Chan
Guidelines Chair
March 2026